NEW YORK, Dec. 11, 2014 (GLOBE NEWSWIRE) -- AXIM Biotechnologies (OTC:AXIM) is extremely proud to announce the newest appointments to the Company's Advisory Board: Dr. Arno Hazekamp, Ph.D., and Mr. Warren C. Hutchins. Their professional backgrounds will help AXIM Biotechnologies propel the re-emergence of industrial hemp-based consumer products into the global marketplace. Their respective global areas of expertise are in cannabinoid medical research and multi-cultural business development and international finance.
AXIM's Chief Technology Officer Lekhram Changoer states, "AXIM Biotechnologies aims to explore various Active Pharmaceutical Ingredients (APIs) derived from the cannabis plant and their efficacy on medical indications for which currently there is no effective remedy."
Photos accompanying this release are available at
On the pharmaceutical front, AXIM Biotechnologies' focus is currently on two main indications that are under clinical investigation: pain and spasticity in Multiple Sclerosis patients and novel drug delivery systems for Inflammatory Bowel Disease (IBD)/Irritable Bowel Syndrome (IBS) and Crohn's disease.
Changoer continues, "It is our pleasure to announce that the world's most-renowned expert on medical cannabis, Dr. Arno Hazekamp, has joined the Advisory Board of AXIM Biotechnologies. He brings with him extensive knowledge and experience with respect to APIs derived from the cannabis plant and their respective efficacy. Dr. Hazekamp is an internationally recognized and respected medical cannabis promoter who is joining forces with AXIM to further explore and develop the world of medical application for cannabinoids."
Dr. Hazekamp is presently the Head of Research and Development of Bedrocan, BV in The Netherlands. There he works on the preparation of clinical trials with medical cannabis. Involved in the early phase of Echo Pharmaceuticals, a Dutch pharmaceutical company, Dr. Hazekamp's work furthered the development of sublingual delivery system for cannabinoids. His work on validation studies on the Volcano™ vaporizer helped to establish it as a widely used medical device. Since 2009, he has been a board member of the International Association for Cannabis as Medicine (IACM). Dr. Hazekamp is one of the newest appointees to the AXIM Biotechnologies Board of Advisors.
George E. Anastassov, MD, DDS, MBA and Chief Executive Officer for AXIM Biotechnologies states, "AXIM Biotechnologies is building a powerful global presence in the industrial hemp industry and biotechnologies. We sincerely appreciate the wisdom and experience that our Board of Advisors brings to our Company and to the world. It is with extreme pleasure that we are able to announce that Mr. Warren C. Hutchins has joined AXIM Biotechnologies' Board of Advisors."
Warren C. Hutchins is a powerhouse when it comes to leadership and cultivating international business relations. From the Pacific to Europe and from the Middle East to South and North America, Hutchins' career has spanned the globe for nearly three decades. Following his passion for establishing international finance market presence for companies including Citibank and Merrill Lynch, Hutchins also turned his attention to benefiting the community through philanthropic endeavors. His civic leadership has assisted a dozen charitable, cultural/musical and educational institutions around the world. Hutchins is now focusing his attention on assisting AXIM Biotechnologies through the Company's Board of Advisors.
Dr. Anastassov continues, "Warren's career spans the globe as an energetic leader and skilled financial deal maker. He has had a long and distinguished banking career where he built successful teams working in multi-cultural and international environments. Creating global strategic alliances, Warren has excelled in identifying key relationships and channels leading to profitable agreements with significant financial partners in Asia, Europe, the Middle East and South and North America. Warren's career encompasses extensive periods in commercial, investment and governmental and private banking and bank leaderships. We at AXIM feel extremely privileged to be able to utilize his wealth of financial acumen for the benefit of our company and shareholders."
Dr. Anastassov concludes, "Our collective goal is advancing cannabinoid-based sciences to benefit mankind and the environment. We are thrilled about AXIM Biotechnologies' momentum toward achieving this goal."
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@AXIMBiotechnologies.com or call 858-380-5478.
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute industrial hemp-based products.
CONTACT: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Source:AXIM Biotechnologies, Inc